)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Aurobindo Pharma (AUROPHARMA) investor relations material
Aurobindo Pharma Q1 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 25/26 earnings summary5 Aug, 2025
Executive summary
Revenue grew 4% year-over-year to INR 7,868 crore, driven by strong European and growth market performance, with US business stable despite headwinds.
EBITDA reached INR 1,603 crore (20.4% margin), with operational efficiencies and stable gross margins.
Net profit declined 10.2% year-over-year to INR 824 crore, impacted by lower US sales and higher overheads.
Net cash position improved to $140 million as of June 2025, reflecting strong cash generation and reduced gross debt.
Board approved an interim dividend of INR 4.0 per share for FY25-26.
Financial highlights
Formulation business grew 7% year-over-year to INR 6,953 crore, 88% of total revenue; API business declined 16% due to pricing and geopolitical pressures.
US revenues declined 4% year-over-year to $408 million, mainly due to lower lenalidomide sales and destocking.
European revenues rose 18% year-over-year to INR 2,338 crore (EUR 241 million); growth markets up 8.8% to INR 772 crore (USD 90 million).
ARV formulation revenue surged 55% year-over-year to INR 355 crore, driven by volume uptick and new tenders.
R&D spend was INR 367 crore (4.7% of revenue), focused on biosimilars and specialty products; net CapEx for the quarter was $73 million.
Outlook and guidance
Management remains optimistic on sustaining growth, supported by volume expansion, new launches, and stable pricing in US and Europe.
Targeting internal EBITDA margin of 20–21% for FY26, with margin improvement expected from new manufacturing sites and bioreactor lines.
First commercial biosimilar supplies to EU markets expected by Q3/Q4 FY26, with multiple filings and US FDA submission planned.
Recent US acquisition expected to strengthen commercial footprint and accelerate growth potential.
Operational initiatives and disciplined execution highlighted as key to future growth.
Explain the 'temporary challenges' in the US.
Assess impact of US acquisition on growth.
What is driving the strong Europe performance?
Biosimilar EU launch strategy & margins?
Lannett acquisition: FTC risks & synergies?
PenG plant: Ramp-up, yields, & PLI outlook?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Aurobindo Pharma earnings date
Q2 202614 Nov, 2025
Next Aurobindo Pharma earnings date
Q2 202614 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Aurobindo Pharma Limited is an Indian pharmaceutical company engaged in the research, development, manufacturing, and marketing of a wide range of generic medicines. The company’s product portfolio includes antibiotics, antiretrovirals, cardiovascular drugs, central nervous system agents, gastroenterology products, and anti-allergics, among others. Aurobindo Pharma serves markets globally, supplying generic pharmaceuticals to hospitals, pharmacies, and healthcare providers. The company also produces active pharmaceutical ingredients (APIs) and has expanded into specialty drugs and biosimilars. The company is headquartered in Hyderabad, India, and its shares are listed on the NSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage